Glycans in sera of amyotrophic lateral sclerosis patients and their role in killing neuronal cells

PLoS ONE

Volumn 7, Issue 5, 2012, Pages

  Edri Brami, Meital ^a   Rosental, Benyamin ^a   Hayoun, Dana ^a   Welt, Michael ^a   Rosen, Hila ^a   Wirguin, Itzhak ^a   Nefussy, Beatrice ^b   Drory, Vivian E ^b   Porgador, Angel ^a   Lichtenstein, Rachel G ^a  

^a BEN GURION UNIVERSITY OF THE NEGEV   (Israel)

^b TEL AVIV UNIVERSITY   (Israel)

Author keywords

[No Author keywords available]

Indexed keywords

CD16 ANTIGEN; GLYCAN DERIVATIVE; GLYCOPROTEIN; IMMUNOGLOBULIN G; N GLYCAN; UNCLASSIFIED DRUG; FC RECEPTOR; POLYSACCHARIDE;

ADULT; AGED; AMYOTROPHIC LATERAL SCLEROSIS; ANIMAL CELL; ANIMAL TISSUE; ANTIBODY DEPENDENT CELLULAR CYTOTOXICITY; ANTIGEN EXPRESSION; ARTICLE; BLOOD LEVEL; BRAIN TISSUE; CELL ACTIVATION; CELL KILLING; CLINICAL ARTICLE; CONTROLLED STUDY; EFFECTOR CELL; FEMALE; FUCOSYLATION; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MALE; MICROGLIA; MOTOR CORTEX; MOUSE; NERVE CELL LESION; NONHUMAN; PROTEIN GLYCOSYLATION; SIALYLATION; SPINAL CORD; SYNAPSE; ANIMAL; BLOOD; BRAIN; CELL DEATH; CHEMISTRY; GENE EXPRESSION REGULATION; IMMUNOLOGY; LYMPHOCYTE; METABOLISM; MIDDLE AGED; NERVE CELL; PATHOLOGY; TIME; TRANSPORT AT THE CELLULAR LEVEL; TUMOR CELL LINE;

MUS;

ADULT; AGED; AGED, 80 AND OVER; AMYOTROPHIC LATERAL SCLEROSIS; ANIMALS; ANTIBODY-DEPENDENT CELL CYTOTOXICITY; BIOLOGICAL TRANSPORT; BRAIN; CELL DEATH; CELL LINE, TUMOR; FEMALE; GENE EXPRESSION REGULATION; GLYCOPROTEINS; HUMANS; LYMPHOCYTES; MALE; MICE; MICROGLIA; MIDDLE AGED; NEURONS; POLYSACCHARIDES; RECEPTORS, IGG; SPINAL CORD; SYNAPSES; TIME FACTORS;

EID: 84861603970     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0035772     Document Type: Article

References (51)

1. Rudd PM, Leatherbarrow RJ, Rademacher TW, Dwek RA, (1991) Diversification of the IgG molecule by oligosaccharides. Mol Immunol 28: 1369-1378.
2. Nimmerjahn F, Ravetch JV, (2008) Fcgamma receptors as regulators of immune responses. Nat Rev Immunol 8: 34-47.
3. Arnold JN, Warmald MR, Sim RB, Rudd PM, Dwek RA, (2007) The impact of glycosylation on the biological function and structural of human immunoglobulins. Annu Rev Immunol 25: 21-50.
4. Raju TS, (2008) Terminal sugars of Fc glycans influence antibody effector functions of IgGs. Curr Opin Immunol 20: 471-478.
5. Donnenfeld H, Kascsak RJ, Bartfeld H, (1984) Deposits of IgG and C3 in the spinal cord and motor cortex of ALS patients. J. Neuroimmunol 6: 51-57.
6. Engelhardt JI, Appel SH, (1990) IgG reactivity in the spinal cord and motor cortex in amyotrophic lateral sclerosis. Arch Neurol 47: 1210-1206.
7. Mohamed HA, Mosier DR, Zou LL, Siklós L, Alexianu ME et al, (2002) Immunoglobulin Fc gamma receptor promotes immunoglobulin uptake, immunoglobulin-mediated calcium increase, and neurotransmitter release in motor neurons. J Neurosci Res 69: 110-116.
8. Polymenidou M, Cleveland DW, (2008) Motor neuron disease: The curious ways of ALS. Nature 454: 284-285.
9. Engelhardt JI, Tajti J, Appel SH, (1993) Lymphocytic infiltrates in the spinal cord in amyotrophic lateral sclerosis. Arch Neurol 50: 30-36.
10. Alexianu ME, Kozovska M, Appel SH, (2001) Immune reactivity in a mouse model of familial ALS correlates with disease progression. Neurol 57: 1282-1289.
11. Henkel JS, Engelhardt JI, Siklós L, Simpson EP, Kim SH et al, (2004) Presence of dendritic cells, MCP-1 and activated microglia/macrophages in amyotrophic lateral sclerosis spinal cord tissue. Ann Neurol 55: 221-235.
12. Banerjee R, Mosley RL, Reynolds AD, Dhar A, Jackson-Lewis V et al, (2008) Adaptive immune neuroprotection in G93A-SOD1 amyotrophic lateral sclerosis mice. PLoS One 3: e2740.
13. Beers DR, Henkel JS, Zhao W, Wang J, Appel SH, (2008) CD4+ T cells support glial neuroprotection, slow disease progression, and modify glial morphology in an animal model of inherited ALS. Proc Natl Acad Sci USA 105: 15558-15563.
14. Schwartz M, Shechter R, (2010) Systemic inflammatory cells fight off neurodegenerative disease. Nat Rev Neurol 6: 405-410.
15. Henkel JS, Beers DR, Zhao W, Appel SH, (2009) Microglia in ALS: the good, the bad, and the resting. J Neuroimmune Pharmacol 4: 389-398.
16. Wilcock DM, Rojiani A, Rosenthal A, Levkowitz G, Subbarao S et al, (2004) Passive amyloid immunotherapy clears amyloid and transiently activates microglia in a transgenic mouse model of amyloid deposition. J Neurosci 24: 6144-6151.
17. Küster B, Wheeler SF, Hunter PA, Dwek RA, Harvey DJ, (1997) Sequencing of N-glycan oligosaccharides directly from protein gels: In gel deglycosylation and analyzing in HPLC and MALDI-TOF MS. Anal Biochem 250: 82-91.
18. Avidan A, Perlmutter M, Tal S, Oraki O, Kapp T et al, (2009) Differences in the sialylation patterns of membrane stress proteins in chemical carcinogen-induced tumors developed in BALB/c and IL-1alpha deficient mice. Glycoconj J 26: 1181-1195.
19. Hershkovitz O, Rosental B, Rosenberg LA, Navarro-Sanchez ME, Jivov S et al, (2009) NKp44 receptor mediates interaction of the envelope glycoproteins from the West Nile and dengue viruses with NK cells. J Immunol 183: 2610-2621.
20. Cohen M, Elkabets M, Perlmutter M, Porgador A, Voronov E et al, (2010) Sialylation of 3-methylcholanthrene-induced fibrosarcoma determines antitumor immune responses during immunoediting. J Immunol 185: 5869-5878.
21. Lev N, Ickowicz D, Barhum Y, Melamed E, Offen D, (2009) DJ-1 changes in G93A-SOD1 transgenic mice: implications for oxidative stress in ALS. J Mol Neurosci 38: 94-102.
22. Engelhardt JI, Soós J, Obál I, Vigh L, Siklós L, (2005) Subcellular localization of IgG from the sera of ALS patients in the nervous system. Acta Neurol Scand 112: 126-133.
23. Appel SH, Smith RG, Alexianu M, Siklós L, Engelhardt J et al, (1995) Increased intracellular calcium triggered by immune mechanisms in amyotrophic lateral sclerosis. Clin Neurosci 3: 368-374.
24. Alexianu ME, Ho BK, Mohamed AH, La Bella V, Smith RG et al, (1996) The role of calcium-binding proteins in selective motoneuron vulnerability in amyotrophic lateral sclerosis. Ann Neurol 36: 846-858.
25. Demestre M, Pullen A, Orrell RW, Orth M, (2005) ALS-IgG-induced selective motor neurone apoptosis in rat mixed primary spinal cord cultures. J Neurochem 94: 268-275.
26. Mandelboim O, Lieberman N, Lev M, Paul L, Arnon TI et al, (2001) Recognition of haemagglutinins on virus-infected cells by NKp46 activates lysis by human NK cells. Nature 409: 1055-1060.
27. Tzur Y, Marcovich A, Lichtenstein RG, (2008) A two-dimensional array for simultaneous sequencing of N- and O-glycans and their glycoforms on specific glycosylation sites. J Proteome Res 7: 1188-1198.
28. Scholl PR, Ahern D, Geha RS, (1992) Protein tyrosine phosphorylation induced via the IgG receptors Fc gamma Ri and Fc gamma RII in the human monocytic cell line THP-1. J Immunol 149: 1751-1757.
29. Alavi A, Axford JS, (2008) Sweet and sour: the impact of sugars on disease. Rheumatol 47: 760-770.
30. Botella-López A, Burgaya F, Gavín R, García-Ayllón MS, Gómez-Tortosa E et al, (2006) Reelin expression and glycosylation patterns are altered in Alzheimer's disease. Proc Natl Acad Sci USA 103: 5573-5578.
31. Silveyra MX, Cuadrado-Corrales N, Marcos A, Barquero MS, Rábano A, Calero M et al, (2006) Altered glycosylation of acetylcholinesterase in Creutzfeldt-Jakob disease. J Neurochem 96: 97-104.
32. Brettschneider J, Mogel H, Lehmensiek V, Ahlert T, Süssmuth S et al, (2008) Proteome analysis of cerebrospinal fluid in amyotrophic lateral sclerosis (ALS). Neurochem Res 33: 2358-2363.
33. Brettschneider J, Lehmensiek V, Mogel H, Pfeifle M, Dorst J et al, (2010) Proteome analysis reveals candidate markers of disease progression in amyotrophic lateral sclerosis (ALS). Neurosci Lett 468: 23-27.
34. Saldova R, Royle L, Radcliffe CM, Abd Hamid UM, Evans R et al, (2007) Ovarian cancer is associated with changes in glycosylation in both acute-phase proteins and IgG. Glycobiology 17: 1344-1356.
35. Storr SJ, Royle L, Chapman CJ, Hamid UM, Robertson JF et al, (2008) The O-linked glycosylation of secretory/shed MUC1 from an advanced breast cancer patient's serum. Glycobiology 18: 456-62.
36. Okuyama N, Ide Y, Nakano M, Nakagawa T, Yamanaka K et al, (2006) Fucosylated haptoglobin is a novel marker for pancreatic cancer: a detailed analysis of the oligosaccharide structure and a possible mechanism for fucosylation. Int J Cancer 118: 2803-8.
37. Comunale MA, Wang M, Hafner J, Krakover J, Rodemich L et al, (2009) Identification and development of fucosylated glycoproteins as biomarkers of primary hepatocellular carcinoma. J Proteome Res 8: 595-602.
38. An HJ, Kronewitter SR, de Leoz ML, Lebrilla CB, (2009) Glycomics and disease markers. Review. Curr Opin Chem Biol 13: 601-7.
39. Kaneko Y, Nimmerjahn F, Ravetch JV, (2006) Anti-inflammatory activity of immunoglobulin G resulting from Fc sialylation. Science 313: 670-673.
40. Anthony RM, Nimmerjahn F, Ashline DJ, Reinhold VN, Paulson JC et al, (2008) Recapitulation of IVIG anti-inflammatory activity with a recombinant IgG Fc. Science 320: 373-6.
41. Shields RL, Lai J, Keck R, O'Connell LY, Hong K et al, (2002) Lack of fucose on human IgG1 N-linked oligosaccharide improves binding to human Fcgamma RIII and antibody-dependent cellular toxicity. J Biol Chem 277: 26733-26740.
42. Appel SH, Smith RG, Engelhardt JI, Stefani E, (1994) Evidence for autoimmunity in amyotrophic lateral sclerosis. Review J Neurol Sci 124: 14-9.
43. Parekh RB, Dwek RA, Sutton BJ, Fernandes DL, Leung A et al, (1985) Association of rheumatoid arthritis and primary osteoarthritis with changes in the glycosylation pattern of total serum IgG. Nature 316: 452-7.
44. Routier FH, Davies MJ, Bergemann K, Hounsell EF, (1997) The glycosylation pattern of humanized IgGI antibody (D1.3) expressed in CHO cells. Glycoconj J 14: 201-7.
45. Nimmerjahn F, Anthony RM, Ravetch JV, (2007) Agalactosylated IgG antibodies depend on cellular Fc receptors for in vivo activity. Proc Natl Acad Sci USA 104: 8433-8437.
46. Umaña P, Jean-Mairet J, Moudry R, Amstutz H, Bailey JE, (1999) Engineered glycoforms of an antineuroblastoma IgG1 with optimized antibody-dependent cellular cytotoxic activity. Nat Biotechnol 17: 176-80.
47. Schuster M, Umana P, Ferrara C, Brünker P, Gerdes C et al, (2005) Improved effector functions of a therapeutic monoclonal Lewis Y-specific antibody by glycoform engineering. Cancer Res 65: 7934-7941.
48. Yi FH, Lautrette C, Vermot-Desroches C, Bordessoule D, Couratier P et al, (2000) In vitro induction of neuronal apoptosis by anti-Fas antibody-containing sera from amyotrophic lateral sclerosis patients. J Neuroimmunol 109: 211-220.
49. Couratier P, Yi FH, Preud'homme JL, Clavelou P, White A et al, (1998) Serum autoantibodies to neurofilament proteins in sporadic amyotrophic lateral sclerosis. J Neurol Sci 154: 137-45.
50. Sengun IS, Appel SH, (2003) Serum anti-Fas antibody levels in amyotrophic lateral sclerosis. J Neuroimmunol 142: 137-140.
51. Kawashima I, Tada N, Fujimori T, Tai T, (1990) Monoclonal antibodies to disialogangliosides: characterization of antibody-mediated cytotoxicity against human melanoma and neuroblastoma cells in vitro. J Biochem 108: 109-115.